Kronos Bio Corp (KRON): קונצנזוס שווי הוגן

This price action chart on GURU.Markets demonstrates quotes for Kronos Bio, Inc. (KRON), where the indicator stands at 1.00. The business focuses on targeting oncogenic transcription factors, anticipating success in SYK inhibitor trials for leukemia. Currently, Kronos Bio, Inc. (KRON) is allocating funds toward small molecule R&D, which is driving up costs; however, future outsourced drug synthesis promises high margins without the need for capital expenditures in manufacturing plants.

This metric reflects the arithmetic mean of expert expectations regarding the fair value of the security, measuring the asset's fundamental growth potential or overvaluation. By analyzing the aggregated share price forecast, an investor can see the impact of the Kronos Bio (KRON) ESG strategy on capitalization, where adherence to bioethics and sustainable production become risk-mitigating factors that support target price levels over the long term.